A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects With Severe Renal Impairment and Healthy Matched Control Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Oct 2017
At a glance
- Drugs Cabotegravir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 08 Oct 2017 Results presented at the IDWeek 2017
- 15 Dec 2016 Status changed from active, no longer recruiting to completed.
- 09 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Nov 2016.